Colorado’s Prescription Drug Affordability Board voted Friday (Feb. 16) that Amgen’s Enbrel, used to treat various forms of arthritis and psoriasis, is “unaffordable,” and that Gilead Sciences’ Genvoya, a medication for HIV, was “not unaffordable.” The board is set to determine whether it will impose an upper payment limit on Enbrel on Friday (Feb. 23) -- a potentially precedent-setting move that is being closely watched by drug-price control advocates and the drug industry as other states consider setting up similar...